百奥泰(688177)
 
 
  日线
顶尖财经网欢迎您!
  K线
 
 最新动态
  投资评级

研究机构 评级日期 最新评级 上次评级
华鑫证券 2024-04-08 买入
太平洋证券 2024-04-08 买入
德邦证券 2024-04-02 买入
中信建投证券 2024-03-30 买入
  盈利预测
据百奥泰四季报分析:

  盈利能力维持稳定,主营获利能力大幅增强

  成长能力明显改善,营业收入由亏转盈

  偿债能力有所加强,短期债务风险存在但可以控制

  运营能力维持稳定,资金使用效率得到显著提高

  现金流能力有所加强,销售回款能力有较大增强

  财务数据
    截至2024年第一季度实现净利润-1.19亿元,每股收益-0.29元。

    截至2024年第一季度最新股东权益109372.12万元,未分配利润-237471.10万元。

    截至2024年第一季度最新总资产225922.11万元,负债116549.98万元。

利润表
报告期2024-03-312023-12-312023-09-302023-06-30
营业总收入161,591,937.51704,794,652.84461,050,213.9314,666,473.81
营业总成本284,395,134.381,174,540,313.71879,482,469.75599,342,796.17
营业利润-118,876,176.89-389,666,959.73-377,401,839.61-248,830,511.51
利润总额-118,958,055.48-394,423,711.96-382,180,237.12-253,620,873.26
净利润-118,958,055.48-394,531,428.45-382,180,237.12-253,620,873.26
其他综合收益-36,128-8,366.0252,531.6366,881.24
综合收益总额-118,994,183.48-394,539,794.47-382,127,705.49-253,553,992.02
资产负债表
报告期2024-03-312023-12-312023-09-302023-06-30
流动资产合计962,848,038.441,010,400,116.571,077,255,977.491,152,923,864.61
非流动资产合计1,296,373,040.521,276,697,740.211,256,245,615.741,130,371,883.77
资产总计2,259,221,078.962,287,097,856.782,333,501,593.232,283,295,748.38
流动负债合计879,038,435.8725,416,510.73768,652,943.99687,867,210.7
非流动负债合计286,461,406.03348,965,925.44339,721,139.65241,727,314.62
负债合计1,165,499,841.831,074,382,436.171,108,374,083.64929,594,525.32
归属于母公司股东权益合计1,093,721,237.131,212,715,420.611,225,127,509.591,353,701,223.06
股东权益合计1,093,721,237.131,212,715,420.611,225,127,509.591,353,701,223.06
负债和股东权益合计2,259,221,078.962,287,097,856.782,333,501,593.232,283,295,748.38
现金流量表
报告期2024-03-312023-12-312023-09-302023-06-30
经营活动现金流入小计220,108,577.59731,372,664.69576,005,249.76391,982,890.66
经营活动现金流出小计284,911,732.621,192,243,226.62934,151,429.86610,669,776.25
经营活动产生的现金流量净额-64,803,155.03-460,870,561.93-358,146,180.1-218,686,885.59
投资活动现金流入小计441,860,214.381,844,709,430.981,557,960,978.921,145,141,626
投资活动现金流出小计273,243,851.991,807,137,019.191,418,094,540.641,059,448,613.86
投资活动产生的现金流量净额168,616,362.3937,572,411.79139,866,438.2885,693,012.14
筹资活动现金流入小计134,282,087.44441,849,563.91427,648,244.22250,107,688.84
筹资活动现金流出小计60,129,901.8346,693,489.7830,760,761.525,852,178.94
筹资活动产生的现金流量净额74,152,185.61395,156,074.13396,887,482.7244,255,509.9
汇率变动对现金及现金等价物的影响-44,051.6565,627.34638,579.39601,151.98
现金及现金等价物净增加额177,921,341.37-27,576,448.67179,246,320.27111,862,788.43
期末现金及现金等价物余额295,742,853.65117,821,512.28324,644,281.22257,260,749.38
  主营收入+营业利润
 
  净利润+每股收益
  股东权益+未分配利润
 
  总资产+负债
  投资要点

    截至2024年第一季度实现净利润-1.19亿元,每股收益-0.29元。

    截至2024年第一季度最新股东权益109372.12万元,未分配利润-237471.10万元。

    截至2024年第一季度最新总资产225922.11万元,负债116549.98万元。

利润表
报告期2024-03-312023-12-312023-09-302023-06-30
营业总收入161,591,937.51704,794,652.84461,050,213.9314,666,473.81
营业总成本284,395,134.381,174,540,313.71879,482,469.75599,342,796.17
营业利润-118,876,176.89-389,666,959.73-377,401,839.61-248,830,511.51
利润总额-118,958,055.48-394,423,711.96-382,180,237.12-253,620,873.26
净利润-118,958,055.48-394,531,428.45-382,180,237.12-253,620,873.26
其他综合收益-36,128-8,366.0252,531.6366,881.24
综合收益总额-118,994,183.48-394,539,794.47-382,127,705.49-253,553,992.02
资产负债表
报告期2024-03-312023-12-312023-09-302023-06-30
流动资产合计962,848,038.441,010,400,116.571,077,255,977.491,152,923,864.61
非流动资产合计1,296,373,040.521,276,697,740.211,256,245,615.741,130,371,883.77
资产总计2,259,221,078.962,287,097,856.782,333,501,593.232,283,295,748.38
流动负债合计879,038,435.8725,416,510.73768,652,943.99687,867,210.7
非流动负债合计286,461,406.03348,965,925.44339,721,139.65241,727,314.62
负债合计1,165,499,841.831,074,382,436.171,108,374,083.64929,594,525.32
归属于母公司股东权益合计1,093,721,237.131,212,715,420.611,225,127,509.591,353,701,223.06
股东权益合计1,093,721,237.131,212,715,420.611,225,127,509.591,353,701,223.06
负债和股东权益合计2,259,221,078.962,287,097,856.782,333,501,593.232,283,295,748.38
现金流量表
报告期2024-03-312023-12-312023-09-302023-06-30
经营活动现金流入小计220,108,577.59731,372,664.69576,005,249.76391,982,890.66
经营活动现金流出小计284,911,732.621,192,243,226.62934,151,429.86610,669,776.25
经营活动产生的现金流量净额-64,803,155.03-460,870,561.93-358,146,180.1-218,686,885.59
投资活动现金流入小计441,860,214.381,844,709,430.981,557,960,978.921,145,141,626
投资活动现金流出小计273,243,851.991,807,137,019.191,418,094,540.641,059,448,613.86
投资活动产生的现金流量净额168,616,362.3937,572,411.79139,866,438.2885,693,012.14
筹资活动现金流入小计134,282,087.44441,849,563.91427,648,244.22250,107,688.84
筹资活动现金流出小计60,129,901.8346,693,489.7830,760,761.525,852,178.94
筹资活动产生的现金流量净额74,152,185.61395,156,074.13396,887,482.7244,255,509.9
汇率变动对现金及现金等价物的影响-44,051.6565,627.34638,579.39601,151.98
现金及现金等价物净增加额177,921,341.37-27,576,448.67179,246,320.27111,862,788.43
期末现金及现金等价物余额295,742,853.65117,821,512.28324,644,281.22257,260,749.38
  十大流通股东
十大流通股东 报告期:2024-03-31
股东名称 持股数量(万股) 占总股本比例(%) 上期持股变化(万股)
广州七喜集团有限公司15999.0338.640.00
Therabio International Limited4717.7711.390.00
广州启奥兴投资合伙企业(有限合伙)2317.335.600.00
广州中科粤创孵化器投资管理有限公司-广州中科粤创三号创业投资合伙企业(有限合伙)2133.335.150.00
东台市启恒医药合伙企业(有限合伙)1999.184.83-17.00
广州晟昱投资合伙企业(有限合伙)1600.003.860.00
易良昱1176.002.840.00
广州返湾湖投资合伙企业(有限合伙)742.461.790.14
SHENGFENG LI651.731.570.00
汇天泽投资有限公司456.091.100.00
  主力控盘
  公司简介
百奥泰 所属地域: 广东省 涉及概念: 沪股通,创新药,生物医药,融资融券
主营业务: 医学研究和试验发展;技术服务、技术开发、技术咨询、技术交流、技术转让、技术推广;细胞技术研发和应用;药品委托生产;药品生产;货物进出口;技术进出口;药品进出口;药品零售。
上市日期: 2020-02-21 每股净资产: 2.64元 每股收益: -0.29元 净利润: -1.19亿元 净利润增长率: 16.57%
营业收入: 1.62亿元 每股现金流: -0.16元 每股公积金: 7.38元 每股未分配利润: -5.73元 总股本: 4.14亿 流通股: 4.14亿
以上信息为合作方、加盟公司及会员收集,本站不拥有版权,版权归原作者所有,所载文章、数据仅供参考,据此操作,风险自负。

中 华 顶 尖 财 经 -- 中 华 顶 尖 网 络 信 息 服 务 中 心